Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis

Clinical Cancer Research

Volumn 14, Issue 9, 2008, Pages 2878-2886

  Yu, Dianke ^a   Zhang, Xuemei ^a   Liu, Ju ^b   Yuan, Peng ^b   Tan, Wen ^a   Guo, Yongli ^a   Sun, Tong ^a   Zhao, Dan ^a   Yang, Ming ^a   Liu, Junniao ^a   Xu, Binghe ^b   Lin, Dongxin ^a,b  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN;

ARTICLE; CANCER RESISTANCE; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DNA REPAIR; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; LUNG CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; ALLELE; CASE CONTROL STUDY; GENE LINKAGE DISEQUILIBRIUM; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; LUNG TUMOR; PROMOTER REGION; SMALL CELL CARCINOMA; TUMOR CELL LINE;

ALLELES; ANTINEOPLASTIC AGENTS; CARCINOMA, SMALL CELL; CASE-CONTROL STUDIES; CELL LINE, TUMOR; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; LUNG NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROMOTER REGIONS (GENETICS);

EID: 46649095015     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1612     Document Type: Article

References (45)

1. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004;350:379-92.
2. Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer 2001;1:22-33.
3. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001;411:366-74.
4. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998;24:331-44.
5. Tsodikov OV, Enzlin JH, Scharer OD, Ellenberger T. Crystal structure and DNA binding functions of ERCC1, a subunit of the DNA structure-specific endo-nuclease XPF-ERCC1. Proc Natl Acad Sci U S A 2005;102:11236-41.
6. Choi YJ, Ryu KS, Ko YM, et al. Biophysical characterization of the interaction domains and mapping of the contact residues in the XPF-ERCC1complex. J Biol Chem 2005;280:28644-52.
7. Gaillard PH, Wood RD. Activity of individual ERCC1 and XPF subunits in DNA nucleotide excision repair. Nucleic Acids Res 2001;29:872-9.
8. Niedernhofer LJ, Odijk H, Budzowska M, et al. The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol 2004;24:5776-87.
9. Niedernhofer LJ, Essers J, Weeda G, et al. The structure-specific endonuclease Ercc1-Xpf is required for targeted gene replacement in embryonic stem cells. EMBO J 2001;20:6540-9.
10. Zhu XD, Niedernhofer L, Kuster B, Mann M, Hoeijmakers JH, de Lange T. ERCC1/XPF removes the 3′ overhang from uncapped telomeres and represses formation of telomeric DNA containing double minute chromosomes. Mol Cell 2003;12:1489-98.
11. Joshi MB, Shirota Y, Danenberg KD, et al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 2005;11:2215-21.
12. Altaha R, Liang X, Yu JJ, Reed E. Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med 2004;14:959-70.
13. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8:2286-91.
14. Wachters FM, Wong LS, Timens W, Kampinga HH, Groen HJ. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer 2005;50:211-9.
15. Kim DY, Cho MS, ChoJ Y, et al. Significance of ercc1 protein expression in predicting response for advanced gastric cancer patients receiving cisplatin containing chemotherapy. Proc Am Soc Clin Oncol 2003;22:1079.
16. Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005;127:978-83.
17. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-91.
18. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007;356:800-8.
19. Vogel U, Dybdahl M, Frentz G, Nexo BA. DNA repair capacity: inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytes. Mutat Res 2000;461:197-210.
20. Li C, Sturgis EM, Eicher SA, Spitz MR, Wei Q. Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck. Cancer 2002;94:393-7.
21. Vogel U, Nexo BA, Tjonneland A, et al. ERCC1, XPD and RAI mRNA levels in lymphocytes are not associated with lung cancer risk in a prospective study of Danes. Mutat Res 2006;29:88-96.
22. Park DJ, Zhang W, Stoehlmacher J, et al. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 2003;1:162-6.
23. Sturgis EM, Dahlstrom KR, Spitz MR, Wei Q. DNA repair gene ERCC1 and ERCC2/XPD polymorphisms and risk of squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2002;128:1084-8.
24. Viguier J, Boige V, Miquel C, et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 2005;11:6212-7.
25. Zhou W, Gurubhagavatula S, Liu G, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small-cell lung cancer patients treated with platinum based chemotherapy. Clin Cancer Res 2004;10:4939-43.
26. Kang S, Ju W, Kim JW, et al. Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer. Exp Mol Med 2006;38:320-4.
27. Zhang X, Miao X, Liang G, et al. Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer. Cancer Res 2005;65:722-6.
28. Liang G, Xing D, Miao X, et al. Sequence variations in the DNA repair gene XPD and risk of lung cancer in a Chinese population. Int J Cancer 2003;105:669-73.
29. Lehmann U, Kreipe H. Real-time PCR analysis of DNA and RNA extracted from formalin-fixed and paraffin-embedded biopsies. Methods 2001;25:409-18.
30. Brennan P. Gene-environment interaction and etiology of cancer: what does it mean and how we measure it? Carcinogenesis 2002;23:381-7.
31. Barrett JC, Fry B, Mailer J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-5.
32. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002;70:425-34.
33. Lake SL, Lyon H, Tantisira K, et al. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered 2003;55:56-65.
34. Wei Q, Frazier ML, Levin B. DNA repair: a double-edged sword. J Natl Cancer Inst 2000;92:440-1.
35. van Duin M, deWit J, Odijk H, et al. Molecular characterization of the human excision repair gene ERCC1: cDNA cloning and amino acid homology with the yeast DNA repair gene RAD10. Cell 1986;44:913-23.
36. Youn CK, Kim MH, Cho HJ, et al. Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents. Cancer Res 2004;64:4849-57.
37. Yan QW, Reed E, Zhong XS Thornton K, Guo Y, Yu JJ. MZF1 possesses a repressively regulatory function in ERCC1 expression. Biochem Pharmacol 2006;71:761-71.
38. Vogel U, Sorensen M, Hansen RD, et al. Gene-environment interactions between smoking and a haplotype of RAI, ASE-1 and ERCC1 polymorphisms among women in relation to risk of lung cancer in a population-based study. Cancer Lett 2007;247:159-65.
39. Matullo G, Dunning AM, Guarrera S, et al. DNA repair polymorphisms and cancer risk in non-smokers in a cohort study. Carcinogenesis 2006;27:997-1007.
40. loannidis JP,Trikalinos TA, Ntzani EE, Contopoulos-loannidis DG. Genetic associations in large versus small studies: an empirical assessment. Lancet 2003;361:567-71.
41. Yu JJ, Mu C, Lee KB, et al. A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mutat Res 1997;382:13-20.
42. Sundstrom S, Bremnes RIM, Kaasa S. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002;20:4665-72.
43. Skarlos DV, Samantas E, Kosmidis P, Fountzilas G, Angelidou M, Palamidas P. Randomised comparison of etoposide-cisplatin versus etoposide-carboplatin and irradiation in small-cell lung cancer: A Hellenic Cooperative Oncology Group Study. Ann Oncol 1994;5:601-7.
44. Yip D, Harper PG. Predictive and prognostic factors in small cell lung cancer: current status. Lung Cancer 2000;28:173-85.
45. Paesmans M, Soulier JP, Lecomte J. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer 2000;89:523-33.